Oncotelic Subsidiary Sapu Nano to Present Everolimus Toxicology Data at Society of Toxicology 2026 Meeting

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation will highlight findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. This research underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.

The presentation at the Society of Toxicology 2026 meeting represents a significant step in understanding how drug distribution at the tissue level impacts toxicity outcomes. Traditional pharmacokinetic studies have primarily focused on plasma concentrations, but this new data examines how drugs accumulate in specific tissues and organs, which can lead to more accurate toxicity assessments. This approach could revolutionize how pharmaceutical companies evaluate drug safety during development phases.

Sapu Nano is developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The company's work on everolimus, a drug used in cancer treatment, demonstrates how nanoparticle-based formulations could potentially reduce toxicity while maintaining or improving therapeutic efficacy. This research aligns with Oncotelic's broader mission to leverage deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients.

The implications of this research extend beyond everolimus specifically. By demonstrating the importance of tissue-level distribution in toxicity profiles, Sapu Nano's findings could influence how all pharmaceutical companies approach drug development and safety testing. The data presented at the Society of Toxicology 2026 meeting may lead to new regulatory considerations for drug approval processes, particularly for cancer treatments where toxicity management is crucial for patient quality of life.

Oncotelic has been building its portfolio through various acquisitions and developments, including the acquisition of PointR Data Inc. in November 2019 to build an AI-driven biotechnology company. The company's focus on rare pediatric cancers, including Diffuse Intrinsic Pontine Glioma through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia through OXi 4503, positions it as a specialized player in oncology therapeutics. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.

The Society of Toxicology 2026 Annual Meeting provides an important platform for sharing these findings with the broader scientific community. As toxicology research evolves to consider more nuanced aspects of drug distribution and effects, presentations like Sapu Nano's contribute to advancing the field. The data on everolimus toxicology could inform future clinical trial designs and treatment protocols, potentially leading to safer and more effective cancer therapies for patients worldwide.